Avalo Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2016 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Avalo Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2016 to Q3 2024.
  • Avalo Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -434 %, a 69% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -434 +968 +69% Sep 30, 2024
Q2 2024 -349 +249 +41.6% Jun 30, 2024
Q1 2024 -292 +358 +55.1% Mar 31, 2024
Q4 2023 1.16K +2.57K Dec 31, 2023
Q3 2023 -1.4K -2.29K -259% Sep 30, 2023
Q2 2023 -598 -921 -285% Jun 30, 2023
Q1 2023 -650 -880 -382% Mar 31, 2023
Q4 2022 -1.41K -1.56K -999% Dec 31, 2022
Q3 2022 883 +761 +619% Sep 30, 2022
Q2 2022 323 +227 +238% Jun 30, 2022
Q1 2022 230 +170 +281% Mar 31, 2022
Q4 2021 156 +101 +183% Dec 31, 2021
Q3 2021 123 +69.1 +129% Sep 30, 2021
Q2 2021 95.4 +16.4 +20.7% Jun 30, 2021
Q1 2021 60.4 -78.5 -56.5% Mar 31, 2021
Q4 2020 55.3 -129 -70.1% Dec 31, 2020
Q3 2020 53.7 -174 -76.4% Sep 30, 2020
Q2 2020 79.1 -156 -66.4% Jun 30, 2020
Q1 2020 139 -93.3 -40.2% Mar 31, 2020
Q4 2019 185 -30.5 -14.2% Dec 31, 2019
Q3 2019 228 +66.7 +41.4% Sep 30, 2019
Q2 2019 235 +124 +111% Jun 30, 2019
Q1 2019 232 +149 +179% Mar 31, 2019
Q4 2018 215 +162 +306% Dec 31, 2018
Q3 2018 161 +86.9 +117% Sep 30, 2018
Q2 2018 112 -501 -81.8% Jun 30, 2018
Q1 2018 83.3 -357 -81.1% Mar 31, 2018
Q4 2017 53 -145 -73.2% Dec 31, 2017
Q3 2017 74.1 -44.1 -37.3% Sep 30, 2017
Q2 2017 612 +1.26K Jun 30, 2017
Q1 2017 440 Mar 31, 2017
Q4 2016 198 Dec 31, 2016
Q3 2016 118 Sep 30, 2016
Q2 2016 -643 Jun 30, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.